My thinking is that the trial will move right along. The data imo will also be presented to the FDA as well. Nothing moves quickly in this sector no matter where the trials are held. The time after the trial to move to the next step, as we've seen with IPIX and just about every bio out there simply is what it is. Lengthy. This is a good start for the UC trial, but still only the first.
News 
Market Data 
Discover 
